INHIBIKASE THERAPEUTICS INC (IKT)
Health Care · biotechnology · NASDAQ
A clinical-stage company developing a novel, oral anti-proliferative prodrug (IKT-001) for the treatment of Pulmonary Arterial Hypertension.
What INHIBIKASE THERAPEUTICS INC does
Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). Its lead candidate, IKT-001, is a prodrug of imatinib mesylate designed to offer an improved gastrointestinal side-effect profile by remaining intact until it reaches the bloodstream. The company is currently conducting a global Phase 3 study, IMPROVE-PAH, to evaluate the efficacy of this candidate.
Recent developments
In July 2026, the FDA granted Orphan Drug Designation to IKT-001, providing development incentives and potential market exclusivity. Additionally, the company raised $50 million in gross proceeds through an at-the-market share sale to RA Capital Management in July 2026 to support its ongoing Phase 3 IMPROVE-PAH trial.
From INHIBIKASE THERAPEUTICS INC's filing of 2026-08-11.
Themes: pulmonary arterial hypertension (PAH), orphan drugs, clinical-stage biopharma
Fundamentals
- Price$1.71 as of 2026-10-20 close
- Market cap$239M as of 2026-08-04 (share count; price 2026-10-20)
- 1-year return+5.6% 2025-10-20 close $1.62 → 2026-10-20 close $1.71
- P/En/a negative earnings
- ROE-27.9% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.43 as of 2026-09-02
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How IKT compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $0 | -$21M | -$20M | -$0.11 | -$12M† | $0† |
| Q1 FY2026 2026-03-31 | $0 | -$18M | -$16M | -$0.10 | -$12M | $0 |
| Q4 FY2025 2025-12-31 | — | -$14M† | -$13M† | -$0.09† | -$8M† | $0† |
| Q3 FY2025 2025-09-30 | $0 | -$13M | -$12M | -$0.13 | -$11M† | $0† |
| Q2 FY2025 2025-06-30 | $0 | -$11M | -$10M | -$0.11 | -$6M† | $0† |
| Q1 FY2025 2025-03-31 | $0 | -$15M | -$14M | -$0.15 | -$4M | $13399 |
| Q4 FY2024 2024-12-31 | — | -$13M† | -$12M† | $0.87† | -$5M† | $0† |
| Q3 FY2024 2024-09-30 | $0 | -$6M | -$6M | -$0.65 | -$5M† | $0† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$31M includes restricted cash (the filer tags no unrestricted total)
- Short-term investments$128M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How INHIBIKASE THERAPEUTICS INC looks technically
INHIBIKASE THERAPEUTICS INC (IKT) is trading 12.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 161 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. It is 34.5% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 12.4% below its 200-day average, the long-term trend line — a long-term downtrend | -12.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.21 | $2.21 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.95 | $1.95 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 47 calendar days ago — the swings before that are what the structure reading is measured on | 47 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 2.61. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 161 trading days ago — a "golden cross", a bullish long-term signal | 161 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 42.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 32.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($1.57 to $2.10) — its "stochastic" reading is 27 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 26.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 48 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $2.61 | $2.61 |
|---|---|---|
| From the 52-week high | it is 34.5% below its 52-week high (its highest price of the past year) | -34.5% |
| Above the 52-week low | it is 28.6% above its 52-week low (its lowest price of the past year) | +28.6% |
| Below the 52-week high | it is 34.5% below its highest point of the past year | 34.5% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $70.80 (set on 2020-12-23) | $70.80 |
| Given back of the 52-week move | over the past year its closes ranged ($1.41 to $2.52), and it has given back well over two thirds of its rise from last year’s low — 73% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $1.80 to $1.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 73.0% |
| From the all-time high | it is 97.6% below its all-time high | -97.6% |
| Nearest price level | it is trading 2.4% below a resistance level at $1.75 — a price it turned at five times since 2024-11-21, most recently on 2026-02-06. Since 2024-10-21 it has 4 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.4% |
| All-time low | its lowest closing price on record is $0.79 (set on 2023-10-10) | $0.79 |
| Above the all-time low | it is 116.5% above its all-time low | +116.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1182 between its high and its low — about 6.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1182 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.63 and $2.21 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.63 – $1.92 – $2.21 |
| Typical daily range (% of price) | its price moves about 6.9% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.9% |
| Stretch from the 200-day average | it is trading 2.1 daily ranges below its 200-day average price (12.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.54× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 7.5% since the prior reading | -7.5% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Gap filled | a 2.9% gap down opened on 2026-08-12 has been "filled" 48 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 48 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 26.6 percentage points (the stock lost 25.7% while the market gained 1.0%) | -26.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 27.0 percentage points (the stock lost 23.3% while the market gained 3.6%) | -26.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.0 percentage points (the stock lost 5.5% while the market gained 8.5%) | -14.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 9.0 percentage points (the stock gained 5.6% while the market gained 14.6%) | -9.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -24.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 10% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.90 — a volume-weighted average of daily closes over 196 sessions, not a true tick-by-tick VWAP. | -9.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.15 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -20.4% |
Price levels it has turned at before
IKT last closed at $1.71 on 2026-10-20. Since 2024-10-21 it has turned at 4 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $1.75 | Resistance | 2.4% above the last close | turned there five times · 2024-11-21 to 2026-02-06 |
| $1.78 | Resistance | 4.2% above the last close | turned there three times · 2025-04-22 to 2025-09-19 |
| $1.62 | Support | 5.3% below the last close | turned there twice · 2026-01-20 to 2026-04-21 |
| $1.53 | Support | 10.2% below the last close | turned there twice · 2025-04-07 to 2026-05-19 |
| $1.89 | Resistance | 10.7% above the last close | turned there five times · 2025-01-31 to 2026-01-22 |
| $1.48 | Support | 13.3% below the last close | turned there four times · 2025-09-19 to 2026-02-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $2.61.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 28 trading days, since 2026-09-11.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · Analyst price target recently CUT · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.30 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$5.55 range $1.50 – $8.00; median $5.50
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IKT
- Consensus EPS estimate-$0.125 next reporting period, as of 2026-10-16
- Estimate change, 30 days-$0.01167 from -$0.1133, on 2026-09-11, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no revenue, significant operating losses, and dependence on a single lead candidate, IKT-001.","Drug development is highly uncertain and subject to failure in clinical trials, regulatory rejection, or inability to achieve commercial viability.","Future success is dependent on raising substantial additional capital to fund ongoing and future clinical trials."]
What changed in the latest 10-Q
AI-assisted comparison of IKT's 10-Q filed 2026-08-11 against the prior one filed 2026-05-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-11) adds that Phase 3 study IMPROVE-PAH has '26 country regulatory approvals and 43 clinical sites activated to date, and 3 additional pending country regulatory approvals and 4 planned country regulatory submissions.'
- Newer filing (2026-08-11) adds a Recent Developments paragraph describing May 2026 presentations at the American Thoracic Society International Conference with preclinical and Phase 1 data for IKT-001, including GI side-effect profile findings, c-Kit inhibition data, and dose proportional exposure results.
- Newer filing (2026-08-11) adds a Recent Developments paragraph describing a July 2026 sale of 25,000,000 shares of common stock to RA Capital Management through an ATM facility for gross proceeds of $50.0 million and subsequent exchange of 18,030,000 shares for pre-funded warrants.
- Newer filing (2026-08-11) adds a Recent Developments paragraph stating the FDA granted Orphan Drug Designation for IKT-001 in July 2026 and describing potential development incentives associated with ODD.
- Removed:
- Older filing (2026-05-12) contains a Recent Developments paragraph describing April 2026 announcement of first patient enrolled in IMPROVE-PAH (NCT07365332), regulatory approvals in more than 25 countries, use of FAST-EU pilot initiative, and EMA determination permitting initiation in twelve European countries for a total of sixteen approved countries.
- Older filing (2026-05-12) contains a Recent Developments statement that Inhibikase submitted an Orphan Drug Designation application to the FDA in April 2026.
- Reworded:
- Newer filing (2026-08-11) changes 'is presently enrolling patients' to 'is presently enrolling patients with 26 country regulatory approvals and 43 clinical sites activated to date...' in the Overview section.
- Newer filing (2026-08-11) changes 'our ability to successfully file IND and NDA applications with the FDA' to 'our ability to successfully file Investigational New Drug ("IND") applications with the FDA', removing the NDA reference and adding the IND acronym definition.
- Newer filing (2026-08-11) text is truncated after 'the terms and timing of any milestone paym', while older filing (2026-05-12) continues with additional risk factor bullets including milestone payments thereunder, intellectual property protection, marketing approvals, commercialization, and continued acceptable safety profiles.
- Notes:
- The newer MD&A text appears truncated mid-sentence in the provided excerpt (ending at 'milestone paym'), so changes after that point cannot be assessed.
- The older filing includes additional research and development risk factor bullets that are not present in the newer excerpt, but this may be due to truncation of the newer text rather than actual removal.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for IKT — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IKT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,929,583
- Reported value $20,157,052
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IKT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IKT had 19,430,194 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
IKT had 13.9% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 27.01 days to cover at the same settlement.
- Reported short interest (shares) 19,430,194
- Short interest (% of shares outstanding) 13.9%
- Prior settlement (shares) 18,518,754
- Reported change 4.92%
- Days to cover (reported) 27.01
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- United Therapeutics (UTHR)
- Actelion Pharmaceuticals (JNJ)
- Gilead Sciences (GILD)
- Bayer AG (BAYRY)
- Merck & Co. (MRK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IKT vs…
INHIBIKASE THERAPEUTICS INC is found in…
Frequently asked questions
What does INHIBIKASE THERAPEUTICS INC (IKT) do?
Inhibikase Therapeutics is a clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, specifically Pulmonary Arterial Hypertension (PAH). Its lead candidate, IKT-001, is a prodrug of imatinib mesylate designed to offer an improved gastrointestinal side-effect profile by remaining intact until it reaches the bloodstream. The company is currently conducting a global Phase 3 study, IMPROVE-PAH, to evaluate the efficacy of this candidate.
What sector is INHIBIKASE THERAPEUTICS INC (IKT) in?
INHIBIKASE THERAPEUTICS INC (IKT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are INHIBIKASE THERAPEUTICS INC's (IKT) competitors?
Notable peers of INHIBIKASE THERAPEUTICS INC (IKT) include United Therapeutics, Actelion Pharmaceuticals, Gilead Sciences, Bayer AG and Merck & Co.. This peer set is informational only — not financial advice.
Is INHIBIKASE THERAPEUTICS INC (IKT) overbought or oversold right now?
INHIBIKASE THERAPEUTICS INC (IKT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IKT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.